RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering RNAi Platform
News May 24, 2014
RXi Pharmaceuticals Corporation has announced that it has received the Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA®).
The patent, titled "Reduced Size Self-Delivering RNAi Compounds", broadly covers both the composition and methods of use of RXi's self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029.
This core patent, within RXi's intellectual property portfolio, is the foundation for RXI's self-delivering platform. The patent broadly protects RXi's sd‑rxRNA technology, which facilitates the delivery of RNAi compounds to tissues and cells of interest in the absence of a delivery vehicle.
sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.
"We are pleased to have our novel technology recognized by the United States Patent and Trademark Office," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "This key patent is what differentiates RXi's technology platform from the competition. It provides us with a powerful advantage to deliver our RNAi compounds without delivery vehicles, which are commonly used with the other siRNA compounds in clinical development. The use of our proprietary sd‑rxRNA technology platform may lead to improved tolerability and thereby potentially broadening of the therapeutic window for these compounds."
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Gene Regulator May Contribute to Protein Pileup in Exfoliation GlaucomaNews
Researchers are seeking factors that contribute to protein pileup in exfoliation glaucomaREAD MORE
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE